866-997-4948(US-Canada Toll Free)

Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : May 2013

Category :

Cancer

No. of Pages : 62 Pages


Global Markets Directs, \'Human papillomavirus (HPV) Associated Cancer Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Human papillomavirus (HPV) Associated Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Human papillomavirus (HPV) Associated Cancer. 

Human papillomavirus (HPV) Associated Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Human papillomavirus (HPV) Associated Cancer.
  • A review of the Human papillomavirus (HPV) Associated Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Human papillomavirus (HPV) Associated Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Human papillomavirus (HPV) Associated Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Human papillomavirus (HPV) Associated Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Human papillomavirus (HPV) Associated Cancer Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Human papillomavirus (HPV) Associated Cancer 9
Human papillomavirus (HPV) Associated Cancer Therapeutics under Development by Companies 11
Human papillomavirus (HPV) Associated Cancer Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Human papillomavirus (HPV) Associated Cancer Therapeutics - Products under Development by Companies 18
Human papillomavirus (HPV) Associated Cancer Therapeutics - Products under Investigation by Universities/Institutes 19
Companies Involved in Human papillomavirus (HPV) Associated Cancer Therapeutics Development 20
Merck & Co., Inc. 20
Transgene SA 21
Prima BioMed Limited 22
Antigen Express, Inc. 23
PDS Biotechnology Corporation 24
Etubics Corporation 25
iBio, Inc. 26
Sirnaomics, Inc. 27
Cancer Therapeutics CRC Pty Ltd 28
EyeGene, Inc. 29
Vaccibody AS 30
Coridon Pty Ltd 31
Human papillomavirus (HPV) Associated Cancer - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Combination Products 33
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
PDS-0101 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
V-503 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
TG-4001 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
HPV Vaccine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
RBT-201 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
HPV-Head and Neck Cancer Vaccine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
AEH-10p - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
P16_37-63 Vaccine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
EG-HPV - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Human Papillomavirus Vaccine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
STP-911 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Drug Targeting E6AP - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
HPV-16 E6 Peptides + Candin - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
HPV Vaccine - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
VB-1016 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Anti-E6 Protein Antibodies - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Human papillomavirus (HPV) Associated Cancer Therapeutics - Drug Profile Updates 55
Human papillomavirus (HPV) Associated Cancer Therapeutics - Dormant Products 58
Human papillomavirus (HPV) Associated Cancer - Product Development Milestones 59
Featured News & Press Releases 59
Sep 04, 2012: Republic Of Uganda And Merck Launch Cervical Cancer Vaccination Program With Gardasil 59
Feb 28, 2012: Coridon To Develop New HPV Therapeutic Vaccine 59

Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 62
Disclaimer 62

List of Table


Number of Products Under Development for Human papillomavirus (HPV) Associated Cancer, H1 2013 9
Products under Development for Human papillomavirus (HPV) Associated Cancer - Comparative Analysis, H1 2013 10
Number of Products under Development by Companies, H1 2013 12
Number of Products under Investigation by Universities/Institutes, H1 2013 13
Comparative Analysis by Late Stage Development, H1 2013 14
Comparative Analysis by Mid Clinical Stage Development, H1 2013 15
Comparative Analysis by Early Clinical Stage Development, H1 2013 16
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 17
Products under Development by Companies, H1 2013 18
Products under Investigation by Universities/Institutes, H1 2013 19
Merck & Co., Inc., H1 2013 20
Transgene SA, H1 2013 21
Prima BioMed Limited, H1 2013 22
Antigen Express, Inc., H1 2013 23
PDS Biotechnology Corporation, H1 2013 24
Etubics Corporation, H1 2013 25
iBio, Inc., H1 2013 26
Sirnaomics, Inc., H1 2013 27
Cancer Therapeutics CRC Pty Ltd, H1 2013 28
EyeGene, Inc., H1 2013 29
Vaccibody AS, H1 2013 30
Coridon Pty Ltd, H1 2013 31
Assessment by Monotherapy Products, H1 2013 32
Assessment by Combination Products, H1 2013 33
Assessment by Stage and Route of Administration, H1 2013 35
Assessment by Stage and Molecule Type, H1 2013 37
Human papillomavirus (HPV) Associated Cancer Therapeutics - Drug Profile Updates 55
Human papillomavirus (HPV) Associated Cancer Therapeutics - Dormant Products 58

List of Chart


Number of Products under Development for Human papillomavirus (HPV) Associated Cancer, H1 2013 9
Products under Development for Human papillomavirus (HPV) Associated Cancer - Comparative Analysis, H1 2013 10
Products under Development by Companies, H1 2013 11
Products under Investigation by Universities/Institutes, H1 2013 13
Late Stage Products, H1 2013 14
Mid Clinical Stage Products, H1 2013 15
Early Clinical Stage Products, H1 2013 16
Discovery and Pre-Clinical Stage Products, H1 2013 17
Assessment by Monotherapy Products, H1 2013 32
Assessment by Combination Products, H1 2013 33
Assessment by Route of Administration, H1 2013 34
Assessment by Stage and Route of Administration, H1 2013 35
Assessment by Molecule Type, H1 2013 36
Assessment by Stage and Molecule Type, H1 2013 37

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *